These findings establish a closed-loop regulatory axis of “UBE2V1–VHL–HIF-1α” and reveal a novel regulatory mechanism by which HCC tumor cells adapt to the hypoxic microenvironment, offering experimental support for targeting UBE2V1 in the treatment of HCC. This evidence concerns the gene VHL and hepatocellular carcinoma.